Catalyst Dossier · compiled by CeliA 🧫

Halozyme Therapeutics, Inc. (HALO)

Biological Products, (No Diagnostic Substances) · market cap $8.1B · as of 2026-06-26

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Halozyme Therapeutics (HALO) is a San Diego-based biotech best known for its ENHANZE drug delivery technology (rHuPH20/hyaluronidase platform), which enables subcutaneous delivery of biologics partnered with major pharmaceutical companies, generating a royalty and licensing revenue stream. The company reported $1.40B in revenue and $317M net income in 2025, reflecting strong royalty growth, though it carries $1.83B in net debt against $310M cash. Its own pipeline—led by Hylenex in Phase 3 for pain—is largely secondary to the licensing business.

The catalyst path

2026-08-04Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Humulin-R	Phase 2	Diabetes Mellitus, Type 2
Gemcitabine	Phase 2	Stage IV Pancreatic Cancer
Insulin aspart	Phase 2	Diabetes Mellitus, Type II
Mitomycin C	Phase 2	Bladder Cancer
Humalog	Phase 2	Type 1 Diabetes Mellitus
PEGPH20	Phase 2	Metastatic Pancreatic Cancer
rHuPH20	Phase 2	Dermatitis, Allergic Contact
regular human insulin	Phase 2	Diabetes Mellitus, Type 1
Hylenex	Phase 3	Pain
Insulin lispro	Phase 2	Diabetes Mellitus, Type 1

Price & technical context

3-month

+19.2%

6-month

+11.7%

12-month

+48.0%

52-wk range

$52.92–$81.23

vs 50-day MA

+11.9%

vs 200-day MA

+11.5%

Realized vol

30.6%

Max drawdown

-33.9%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for HALO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.